Compare · DXCM vs NYXH
DXCM vs NYXH
Side-by-side comparison of DexCom Inc. (DXCM) and Nyxoah SA (NYXH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NYXH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $30.17B, about 515.7x NYXH ($58.5M).
- Over the past year, DXCM is down 7.8% and NYXH is down 82.5% - DXCM leads by 74.7 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 9 for NYXH).
- DXCM has more recent analyst coverage (25 ratings vs 9 for NYXH).
- Company
- DexCom Inc.
- Nyxoah SA
- Price
- $78.19+2.08%
- $1.36+0.00%
- Market cap
- $30.17B
- $58.5M
- 1M return
- +29.01%
- -58.15%
- 1Y return
- -7.79%
- -82.50%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 26
- 9
- Recent ratings
- 25
- 9
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest NYXH
- SEC Form 6-K filed by Nyxoah SA
- SEC Form 424B5 filed by Nyxoah SA
- SEC Form FWP filed by Nyxoah SA
- Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
- SEC Form 6-K filed by Nyxoah SA
- SEC Form 424B5 filed by Nyxoah SA
- Nyxoah Announces Proposed Offering of Ordinary Shares
- Nyxoah Enters New Chapter of Long Term Value Creation
- Information on the total number of voting rights and shares
- SEC Form 6-K filed by Nyxoah SA